Biosimulation Market To Reach USD 12.7 Billion By 2032 Report By DataHorizzon Research
December 06, 2023 06:40 ET
|
DataHorizzon Research
Fort Collins, Colorado, Dec. 06, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The Biosimulation Market size was valued at USD 2.8 Billion in 2022 and is anticipated to reach USD 12.7...
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
November 21, 2023 16:30 ET
|
Certara
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
September 19, 2023 08:15 ET
|
Certara
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to...
[Latest report] Biosimulation Market is estimated to be US$ 8969.47 million by 2030 with a CAGR of 15.4% during the forecast period – By PMI
September 07, 2023 14:30 ET
|
PMI
Covina, Sept. 07, 2023 (GLOBE NEWSWIRE) -- According to the latest research study, the demand of “Biosimulation Market accounted for US$ 2113.91 million in 2020 and is estimated to be US$ 8969.47...
Certara Simcyp™ Group Awarded Two New Grants from US FDA
August 29, 2023 08:15 ET
|
Certara
PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food...
Certara Reports Second Quarter 2023 Financial Results
August 09, 2023 16:15 ET
|
Certara
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. ...
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
July 13, 2023 16:30 ET
|
Certara
PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...
Biosimulation Market Is Expected to Reach $4.9 billion by 2030, Grow at a CAGR Of 20.1% during Forecast Period 2023 To 2030 | Data By Contrive Datum Insights Pvt Ltd.
May 10, 2023 00:00 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, May 10, 2023 (GLOBE NEWSWIRE) -- The Global Biosimulation Market Was Valued At $1.3 billion In 2022 And Is Expected To Expand $4.9 billion By 2030 at a CAGR Of 20.1% From 2022 To 2030....
Certara Reports First Quarter 2023 Financial Results
May 08, 2023 16:15 ET
|
Certara
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. ...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
April 27, 2023 08:00 ET
|
Certara
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...